相关实验视频

Updated: Jul 13, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

一个具有巨大影响的小分子:MRTX1133针对胰腺癌中KRASG12D突变

Daoyan Wei¹, Liang Wang², Xiangsheng Zuo³

¹Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Clinical cancer research : an official journal of the American Association for Cancer Research

|October 13, 2023

概括

一种名为MRTX1133的新药在治疗KRASG12D突变胰腺癌方面表现有前途. 这种向治疗在临床前研究中显示出显著的抗瘤作用,为一种新的胰腺管腺癌 (PDAC) 治疗提供了希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

KRAS突变是许多癌症的关键驱动因素,特别是胰腺管腺癌 (PDAC),其中G12D和G12V是最常见的.
虽然像索托拉西布这样的KRASG12C抑制剂提供了突破性进展,但急需针对PDAC中其他常见的KRAS突变的治疗方法.

研究的目的:

总结一下MRTX1133的最新进展,这是一种新的KRASG12D抑制剂,用于治疗KRASG12D突变PDAC.
专注于MRTX1133的疗效,机械作用和PDAC治疗中的潜在挑战.

主要方法:

对MRTX1133的临床前数据的审查,它是一种小分子,非共价的KRASG12D抑制剂.
基于结构的药物设计的分析导致了MRTX1133的开发.
目前正在进行的MRTX1133在PDAC中的I/II期临床试验摘要.

主要成果:

MRTX1133在体外和体内具有强大的抗瘤疗效,对抗KRASG12D突变癌细胞,特别是在PDAC模型中.
该药物已进入I/II期临床试验,表明有前途的治疗潜力.
临床前发现表明,MRTX1133可能会对PDAC管理产生重大影响.

结论:

MRTX1133是对KRASG12D突变PDAC的一种有前途的向疗法,显示出显著的临床前抗瘤活性.
未来的方向包括解决耐药性,开发组合疗法和优化药物动力学特性.
MRTX1133有可能彻底改变PDAC治疗,标志着其管理的范式转变.

更多相关视频

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...